SCHEMBL653868

SCHEMBL653868

CCCc1cc(C(=O)N[C@@H](CS)Cc2ccccc2)nn1Cc1ccc(-c2ccccc2-c2nc(=O)o[nH]2)cc1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MME P08473 15/20 0.40
AGTR1 P30556 4/20 0.38
PPARG P37231 1/20 0.36
CTRB1 P17538 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652577 0.88 MME (0.39) MMEPPARG
SCHEMBL1074155 0.88 MME (0.39) MMEPPARG
SCHEMBL652532 0.85 MME (0.40) MMEAGTR1CTRB1
SCHEMBL653074 0.85 PPARG (0.49) MMEAGTR1PPARG
SCHEMBL1928982 0.85 PPARG (0.49) MMEAGTR1PPARG
SCHEMBL3771299 0.84 PPARG (0.45) AGTR1PPARG
SCHEMBL651961 0.79 AGTR2 (0.42) MMEAGTR1
SCHEMBL15253877 0.79 MME (0.49) MMECTRB1
SCHEMBL654625 0.78 MMEL1 (0.41) MME
SCHEMBL654626 0.78 MMEL1 (0.41) MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028305-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US claimed
US-20260028306-A1 PROCESS FOR PRODUCING METHYLENEBIS(CYCLOHEXYLAMINE) EVONIK OPERATIONS GMBH (DE) 2026-01-29 US claimed
US-20260028304-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US claimed
US-20260027536-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US claimed
US-20260027535-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US claimed
EP-4631929-A1 METHOD FOR PRODUCING DIAMINE CONTAINING CYCLOHEXANE RING MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-10-15 EP claimed
WO-2024122528-A1 METHOD FOR PRODUCING DIAMINE CONTAINING CYCLOHEXANE RING 三菱瓦斯化学株式会社 2024-06-13 WO claimed
US-10577512-B2 Compatibilizer for universal colorant in solventborne alkyd paints EVONIK OPERATIONS GMBH (DE) 2020-03-03 US claimed
EP-3305840-B1 COMPATIBILIZER FOR UNIVERSAL COLORANT IN SOLVENTBORNE ALKYD PAINTS EVONIK DEGUSSA GMBH (DE) 2019-11-06 EP claimed
EP-3305840-A1 COMPATIBILIZER FOR UNIVERSAL COLORANT IN SOLVENTBORNE ALKYD PAINTS Evonik Degussa GmbH (DE) 2018-04-11 EP claimed
US-20180094146-A1 COMPATIBILIZER FOR UNIVERSAL COLORANT IN SOLVENTBORNE ALKYD PAINTS EVONIK DEGUSSA GMBH (DE) 2018-04-05 US claimed
EP-3181611-A1 AN ALICYCLIC DI-AMMONIUM DI-CARBOXYLATE SALT Nexam Chemical AB (SE) 2017-06-21 EP claimed
WO-2026099001-A1 ADDITIVE COMPOSITION FOR POWDER COATINGS EVONIK OPERATIONS GMBH (DE) 2026-05-15 WO disclosed
US-20260028307-A1 Process for the hydrogenation of MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US disclosed
US-20260027536-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US disclosed
US-20260027535-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA EVONIK OPERATIONS GMBH (DE) 2026-01-29 US disclosed
US-4841090-A OIL AND WATER RESISTANCE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-06-20 US disclosed
EP-0255990-A2 Polytriazine compounds containing recurring piperidylamidinotriazine structural units and their use as stabilizers for organic materials CIBA-GEIGY AG (CH) 1988-02-17 EP disclosed
EP-0102690-B1 TREATMENT OF FIBROUS SUBSTRATES, SUCH AS CARPET WITH FLUOROCHEMICAL MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-04-08 EP disclosed
EP-0102690-A1 Treatment of fibrous substrates, such as carpet with fluorochemical MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1984-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027535-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA MDH1, MDH2, GPX1 MME 2888/4885AGTR1 2631/4885PPARG 4324/4885
US-20260028305-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA MPO, MDH1, MDH2 MME 3732/4885AGTR1 2715/4885PPARG 3562/4885
US-20260028307-A1 Process for the hydrogenation of MDA MPO, MRM1, DNMT1 MME 2637/4885AGTR1 1632/4885PPARG 3234/4885
US-20260027536-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA MPO, MDH1, MDH2 MME 3376/4885AGTR1 2618/4885PPARG 4035/4885
US-20260028304-A1 PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA MPO, CAT, MDH1 MME 3184/4885AGTR1 1655/4885PPARG 3545/4885
US-20260028306-A1 PROCESS FOR PRODUCING METHYLENEBIS(CYCLOHEXYLAMINE) MVD, PNMT, HNMT MME 308/4885AGTR1 2611/4885PPARG 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.